Avanos Medical Stock (NYSE:AVNS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$19.15

52W Range

$17.39 - $25.36

50D Avg

$22.40

200D Avg

$20.88

Market Cap

$858.48M

Avg Vol (3M)

$231.96K

Beta

0.93

Div Yield

-

AVNS Company Profile


Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

3,771

IPO Date

Oct 21, 2014

Website

AVNS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Digestive Health$371.60M--
Interventional Pain$162.50M--
Pain Management-$343.70M$264.80M
Chronic Care-$476.30M$479.80M
Digestive health-$340.40M$322.20M
Respiratory health-$135.90M$157.60M
Acute pain-$160.10M$162.70M
Interventional pain-$183.60M$102.10M

Fiscal year ends in Dec 23 | Currency in USD

AVNS Financial Summary


Dec 23Dec 22Dec 21
Revenue$673.30M$820.00M$744.60M
Operating Income$52.40M$74.00M$8.90M
Net Income$-61.80M$50.50M$6.30M
EBITDA$98.50M$122.90M$47.40M
Basic EPS$-1.33$1.08$0.13
Diluted EPS$-1.33$1.07$0.13

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 3:28 PM
Q2 24Jul 31, 24 | 1:35 PM
Q1 24May 02, 24 | 12:00 AM

Peer Comparison


TickerCompany
FNAParagon 28, Inc.
ANIKAnika Therapeutics, Inc.
OFIXOrthofix Medical Inc.
SGHTSight Sciences, Inc.
ITGRInteger Holdings Corporation
SRDXSurmodics, Inc.
LIVNLivaNova PLC
NVRONevro Corp.
KIDSOrthoPediatrics Corp.
GKOSGlaukos Corporation
AORTArtivion, Inc.
AXGNAxoGen, Inc.
ESTAEstablishment Labs Holdings Inc.
CNMDCONMED Corporation